The c-fins gene product is related, and possibly identical, to the receptor for the mononuclear phagocyte colony stimulating factor, CSF-1. Using antisera to a recombinant v-fins-coded polypeptide, glycoproteins encoded by the human c-fms locus were detected in mononuclear cells from normal peripheral blood and in promyelocytic HL-60 cells 24 h after induction of monocytic differentiation with phorbol ester. The 150-kD human c-fins-coded glycoprotein was expressed at the cell surface, was active as a tyrosine-specific protein kinase in vitro, and shared primary structural features with the product of the feline retroviral v-fms oncogene. A biochemically indistinguishable glycoprotein was detected in human choriocarcinoma cell lines. Like peripheral blood mononuclear cells and phorbol ester-treated HL-60 cells, the choriocarcinoma cells expressed high affinity binding sites for human CSF-1. In addition to serving as a lineage specific growth factor in hematopoiesis, CSF-1 may play a role in normal trophoblast development.
Introduction
The colony-stimulating factor, CSF-1,' is a hematopoietic growth factor required for the proliferation, differentiation, and survival of cells of the mononuclear phagocyte series (1) . Cells of this lineage (including determined precursors, monoblasts, promonocytes, monocytes, and macrophages) express a single class of high affinity receptors for CSF-1 (2) (3) (4) . Although the CSF-1 receptor is expressed by less mature bone marrow progenitors, the number of receptors per cell increases about 10-fold as the cells become committed to the mononuclear phagocyte lineage (5) . Thus, circulating peripheral blood monocytes express relatively high numbers of CSF-I receptors, and the populations of CSF-l-binding cells in spleen, lymph nodes, and inflammatory exudates correspond in their number and morphology to macrophages (2, 6) . By these criteria, the expression of the CSF-1
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receptor represents a differentiation specific marker of cells of the mononuclear phagocyte lineage.
The purified murine CSF-1 receptor is a 165-kD glycoprotein with an associated tyrosine-specific protein kinase activity (7, 8) , and is similar in its properties to the product ofa feline protooncogene, c-fms (9) . Indeed, the c-fms proto-oncogene product is preferentially expressed at high levels in feline and murine macrophages, specifically binds CSF-1, and, in the presence of the growth factor, is phosphorylated on tyrosine in membrane preparations (10) . Moreover, the product ofthe feline retroviral oncogene, v-fms, retains a CSF-1 binding domain so that v-fmstransformed fibroblasts express high affinity binding sites for the growth factor (11) . These results strongly suggest that the product of the c-fms proto-oncogene and the CSF-1 receptor are closely related, and possibly identical, molecules (10).
Transcripts of c-fms RNA have been detected in spleen, lymph nodes, liver (9) , bone marrow and peripheral blood mononuclear cells (12, 13) and in human tumors of various histologic types (14) . This pattern ofgene expression is consistent with the tissue distribution of normal CSF-l receptor-bearing cells ofthe mononuclear phagocyte lineage and with infiltration of tumor tissues by inflammatory cells. However, c-fms transcripts have also been detected at comparatively high levels in placental tissues (15) and in a human choriocarcinoma cell line established from malignant placental trophoblasts (16) . The latter observations prompted us to examine the c-fms gene product in choriocarcinoma cell lines and to compare its properties to the c-fms-coded glycoprotein expressed in normal human peripheral blood mononuclear cells. The c-fms gene products in both cell types are biochemically indistinguishable, and the cells express high affinity binding sites for human CSF-1.
Methods
Cell lines. The derivation and properties of mink lung cells nonproductively transformed by the Susan McDonough strain of feline sarcoma virus (SM-FeSV) have been previously described (17) . The human BeWo (18) (21) or to granulocytic differen-tiation by dimethylsulfoxide (DMSO) (22 Binding of"2I-human CSF-J to cells. Stage V human urinary CSF-1 was purified, iodinated, and further purified by immunoaffinity chromatography as described (27) . The specific radioactivity of the purified '251-CSF-l used for the binding studies was 1.5 X I04 cpm/ng protein.
Binding studies with either nonadherent or adherent cells were carried out at 2°C in 25 mM Hepes, 0.02% bovine serum albumin in a-MEM lacking bicarbonate, pH 7.4 (6, 27) . Cells were incubated with 10 nM '251-CSF-l for 4 h with or without a 2-h preincubation with 10 nM CSF- Autoradiography of the nonadherent and adherent cells was carried out as described (2, 6) .
Results
Human c-fms products are expressed in peripheral blood mononuclear cells and in TPA-induced HL-60 cells. Rabbit antisera to a recombinant v-fms coded polypeptide synthesized in bacteria reacted specifically with c-fms-coded gene products expressed in normal feline and murine macrophages and precipitated the bona fide murine CSF-1 receptor (10). The same antisera were found to precipitate antigenically crossreactive molecules from human peripheral blood cells. Fig. 1 (Fig. 3 A) , and the human 1 50-kD polypeptide were sensitive to neuraminidase, demonstrating the presence of terminal sialic acid residues. The human 1 50-kD glycoprotein also showed a slight decrease in apparent molecular weight after endoglycosidase H treatment (Fig. 3 B (Fig. 1 A) and were phosphorylated on tyrosine residues (Fig. 2 B) . Digestion with glycosidic enzymes demonstrated that both forms were glycoproteins indistinguishable from the analogous products expressed on peripheral blood mononuclear cells (see Fig. 3 B) .
To compare regions of primary structure adjacent to sites of phosphorylation in vitro, 32 P-labeled molecules phosphorylated in immune complex kinase reactions were digested with trypsin, and the resulting peptides were separated in two dimensions by electrophoresis and chromatography. As shown in Fig. 4, A and B, the labeled tryptic phosphopeptides ofthe human 150 kD proteins from both peripheral blood mononuclear cells and choriocarcinoma cells were identical. The 1 30-kD proteins from both sources yielded the same labeled peptides (data not shown). Moreover, several of the phosphopeptides comigrated with those derived from the v-fins-coded glycoprotein, gplI40v-fins (Fig. 4 C) . A major 32 P-labeled tryptic peptide unique to the retroviral protein (see schematic diagram in Fig. 4 D) (Fig. 5  A) with those derived from virus-coded gpl4Ov-fms (Fig. 5 B) also suggested that the proteins had related primary structures. A mixing experiment (Fig. 5 C) confirmed the presence of a subset of comigrating peptides as well as unique methioninecontaining peptides derived from each molecule (see diagram in Fig. 5 D) . The (26, 28, 30, 31) . To test for expression of c-fins-coded molecules on the surfaces of human cells, live peripheral blood mononuclear cells and BeWo cells were enzymatically radioiodinated, and after detergent lysis, labeled molecules from the plasma membrane were precipitated with antiserum. Fig. 6 (lanes 1 and 2) shows that when this technique was applied to virus-transformed cells, only '251-labeled gpl140v-fms was detected (28, 30) . product of 150 kD was specifically precipitated from human peripheral blood mononuclear cells (lane 4) and from BeWo cells (lane 6), but was not detected with preimmune serum (lanes 3 and 5, respectively). This polypeptide was not evident in immunoprecipitates prepared from TPA-treated HL-60 cells (data not shown), as predicted from the low levels of its expression seen in the immune complex kinase assay (Fig. 1 B) . Also consistent with the results of metabolic labeling and immune complex kinase assays, the human c-fms-coded glycoproteins were detected at significantly lower levels than their viral counterparts.
The human c-fms-coded glycoprotein of 130 kD was not detected at the cell surface in agreement with the previous findings that it lacked mature N-linked oligosaccharide chains (Fig. 3) . Human peripheral blood monocytes and choriocarcinoma cells bind CSF-1. To determine whether cells producing the human c-fms gene product also expressed receptors for CSF-1, binding studies with the radiolabeled growth factor were performed. Human CSF-1 was partially purified from urine, radiolabeled with 125I, and the labeled growth factor was recovered by affinity chromatography using columns prepared with specific antibodies to CSF- quence homology between gpl 40v-fms and gpl SOc-fms also depends on post-translational processing events. Expression of the c-fms gene product on the surfaces of human peripheral blood mononuclear cells was expected, based on the tissue-specific expression of c-fms in the feline system, and the recently defined relationship between the murine c-fmscoded glycoprotein and the receptor for CSF-l (10). Similarly, c-fms transcripts were previously detected in TPA-treated HL-60 cells after they had differentiated to postmitotic, adherent macrophage-like cells (12, 13) . Unlike the results obtained with normal peripheral blood mononuclear cells, reduced levels of gpl SOc-fms relative to gpl 30c-fms were seen in TPA-treated HL-60 cells. These results might reflect the failure of HL-60 cells to differentiate completely in culture or the possibility that phorbol esters downregulate expression ofCSF-1 receptors, reducing the binding ofCSF-1 to macrophages (33) . Taken together, the above results are consistent with the conclusion that c-fms expression in adult tissues is restricted to cells ofthe mononuclear phagocyte lineage. However, c-fms transcripts (16) and protein products were also detected in choriocarcinoma cell lines derived from placental trophoblasts. Although expression of the c-fms gene products in choriocarcinoma cell lines could be related to transformation of trophoblastic cells, c-fms RNA is expressed at relatively high levels in normal placental tissues as well (15) . Therefore, it seems more likely that the c-fms gene product plays a physiologic role in the placenta.
The relationship of the murine c-fms gene product to the CSF-l receptor (10) and the recent demonstration that the vfms oncogene product can itselfbind murine CSF-l (1 1) together suggested that human cells expressing gp I 50c-fins at their surface would specifically bind the growth factor. Purified murine CSF-1 does not bind to high affinity receptors on human mononuclear phagocytes nor support their growth in culture (1) , and the limited availability of human CSF-l precluded detailed studies of its binding to the different human cell populations. However, a comparison of the number of human CSF-1 molecules bound per adherent monocyte (-40,000 binding sites per cell) with the number of binding sites for murine CSF-1 on mouse bone marrow-derived macrophages (-50,000 per cell; see reference 4) suggested that almost all the CSF-1 sites on human peripheral blood monocytes were occupied under the binding conditions used. Furthermore, the binding was irreversible at 2°C, as observed for the binding of CSF-l to murine cells (4), consistent with an interaction of the ligand with a high affinity receptor.
Under the same conditions, the degree of '25I-CSF-I binding by BeWo and TPA-induced HL-60 cells correlated with the levels of expression of gpl 50c-fms, with BeWo cells expressing a relatively high number of binding sites and HL-60 cells expressing very few. Although these correlative data strongly suggest that human gpl 50c-fms is related and possibly identical to the human CSF-l receptor, the limited availability of the purified human hormone precluded more definitive biochemical assays. For example, purified murine '251-CSF-1, when bound to its receptor, was precipitated with antibodies to the murine c-fms product and was shown to enhance phosphorylation ofthe immunoprecipitable receptor on tyrosine (10). Our attempts to generate similar results in the human system were unsuccessful. Since the human CSF-1 gene has been recently cloned and expressed (34) , the availability of recombinant human CSF-l may facilitate such studies.
A clear implication of our data is that CSF-1 could play a role in placental development. Murine CSF-1 levels have been shown to be elevated in uterine tissues during pregnancy (35) , and conceivably, uterine CSF-I could regulate early stages of development with specificity for cells of the fetal placenta that elaborate the receptor. Hence, CSF-I may stimulate embryonic cells that are not committed to the mononuclear phagocyte lineage.
